Oncotype DX
Research shows that the Oncotype DX™ 21-gene assay is effective in predicting the likelihood of disease recurrence within ten years and the magnitude of chemotherapy response in patients with node-negative, estrogen-receptor-positive, early-stage (I or II) breast cancer.
In the chemotherapy benefit study conducted by the National Surgical Adjuvant Breast and Bowel Project B-20, patients with a high risk of breast cancer recurrence, as determined by the Oncotype DX™ assay, derived a large benefit from chemotherapy. Those with a low risk of recurrence derived only a small (if any) benefit from chemotherapy. Those at high risk represented about 25% of patients with node-negative, estrogen-receptor-positive, early-stage breast cancer. Those at low risk represented about 50% of such patients.
The Oncotype DX test is included in the National Comprehensive Cancer Network (NCCN) Breast Cancer Treatment Guidelines, which outlines for physicians recommended methods of treatment and care.